Key Points
- Insider sale: Matthew Henn sold 1,257 shares on Nov. 15 at an average price of $17.30 for $21,746.10, trimming his stake by 14.31% to 7,527 shares.
- Stock snapshot: MCRB opened at $24.71 with a one-year range of $6.53–$25.85, a market cap of $223.6M and a negative P/E of -5.48 (50‑/200‑day SMAs $17.86/$14.08).
- Ownership and outlook: Institutional investors own 59.34% of the stock with recent inflows from firms like Goldman and Vanguard, while analyst coverage is mixed and the consensus rating is "Reduce" with an average price target of $14.33.
Seres Therapeutics, Inc. (NASDAQ:MCRB - Get Free Report) insider Matthew Henn sold 1,257 shares of the business's stock in a transaction on Saturday, November 15th. The shares were sold at an average price of $17.30, for a total transaction of $21,746.10. Following the completion of the sale, the insider directly owned 7,527 shares of the company's stock, valued at approximately $130,217.10. This trade represents a 14.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.
Seres Therapeutics Stock Performance
MCRB opened at $24.71 on Wednesday. Seres Therapeutics, Inc. has a one year low of $6.53 and a one year high of $25.85. The stock has a market capitalization of $223.63 million, a P/E ratio of -5.48 and a beta of 0.19. The business's 50-day simple moving average is $17.86 and its 200-day simple moving average is $14.08.
Institutional Inflows and Outflows
A number of institutional investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. lifted its holdings in shares of Seres Therapeutics by 40.9% during the first quarter. Goldman Sachs Group Inc. now owns 74,629 shares of the biotechnology company's stock worth $52,000 after purchasing an additional 21,679 shares during the period. Schonfeld Strategic Advisors LLC acquired a new position in Seres Therapeutics in the 3rd quarter valued at $557,000. Vanguard Group Inc. raised its position in Seres Therapeutics by 6.8% during the 3rd quarter. Vanguard Group Inc. now owns 311,889 shares of the biotechnology company's stock worth $6,001,000 after buying an additional 19,793 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Seres Therapeutics in the 2nd quarter worth $1,016,000. Finally, Bank of America Corp DE boosted its holdings in shares of Seres Therapeutics by 2,772.6% in the third quarter. Bank of America Corp DE now owns 5,343 shares of the biotechnology company's stock valued at $103,000 after acquiring an additional 5,157 shares in the last quarter. Institutional investors and hedge funds own 59.34% of the company's stock.
Wall Street Analysts Forecast Growth
MCRB has been the subject of a number of research reports. Weiss Ratings reiterated a "sell (d)" rating on shares of Seres Therapeutics in a research note on Monday. Canaccord Genuity Group upped their price target on shares of Seres Therapeutics from $14.00 to $22.00 and gave the company a "buy" rating in a research report on Wednesday, September 24th. One analyst has rated the stock with a Buy rating, one has assigned a Hold rating and two have given a Sell rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Reduce" and an average price target of $14.33.
Get Our Latest Research Report on MCRB
About Seres Therapeutics
(
Get Free Report)
Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
